Somatic mutations in normal and cancer cells
Our team is composed of PhD students, postdoctoral fellows and permanent members of staff including cancer biologists, bioinformaticians, clinical fellows and project management support.
We use DNA sequencing for somatic mutations to advance understanding of the causes of cancer. In particular, we investigate “mutational signatures”, which report the mutational processes operative over the lifetime of each individual, to understand whether they are generated by endogenous or exogenous exposures and the extent to which these vary between human populations.
Our work brings together global cancer epidemiology and genomics and is particularly characterised by large-scale multinational studies.
We currently have two major areas of work:
- Large-scale sequencing of normal and cancer cell genomes to investigate international differences in common mutagenic exposures that may influence cancer incidence.
- Sequencing of normal cell genomes to understand patterns of somatic evolution.
Professor Sir Mike Stratton, FMedSci FRS
Senior Group Leader
Mike's primary research interests are the discovery of genes with inherited mutations in the germline that cause cancer susceptibility, the discovery of somatically mutated genes in cancer that may provide targets for new drug discovery, and understanding the mutational processes and mutational signatures present in normal and cancer cells.